Nuedexta Shortage Update: What Patients Need to Know in 2026

If you have been prescribed Nuedexta (dextromethorphan / quinidine sulfate) for pseudobulbar affect (PBA), you may be wondering whether the difficulty you're having filling it means there's a national shortage. Here is what patients need to know about Nuedexta availability in 2026.

Is Nuedexta in a Formal FDA Shortage in 2026?

No. As of 2026, Nuedexta is not listed on the FDA's official drug shortage database. The FDA Drug Shortages list tracks medications where supply has fallen critically short of demand at the national level, and Nuedexta does not meet that threshold. The manufacturer, Avanir Pharmaceuticals (a subsidiary of Otsuka), continues to produce and distribute Nuedexta.

However, "not in a formal shortage" does not mean "easy to find." Patients continue to report difficulty filling their prescriptions at local retail pharmacies. This access challenge is real — it just has different causes than a traditional drug shortage.

Why Are Patients Having Trouble Getting Nuedexta?

The access challenges most patients face stem from the specialty nature of this drug rather than a production or supply chain issue:

Retail pharmacy stocking gaps. Pharmacies stock based on local demand. With a smaller patient population, many retail locations don't keep Nuedexta on hand.

Prior authorization bottlenecks. Most insurers require prior authorization before covering Nuedexta. The PA process can take days to weeks, delaying treatment starts and refills.

Insurance coverage denials. Some plans have strict step-therapy requirements or deny coverage outright, leaving patients to appeal or pay cash.

High cash price. At over $1,500 per month retail, the cost creates access barriers for uninsured and underinsured patients.

What Does the "No Shortage" Status Mean for Patients?

The good news is that Nuedexta is being manufactured and is available — the problem is distribution and access, not supply. This means that with the right tools and support, most patients can obtain their medication. The drug is available at specialty pharmacies nationwide and through mail-order programs.

What Should Patients Do Right Now?

Here are concrete steps to take if you are struggling to fill your Nuedexta prescription in 2026:

Use medfinder. medfinder calls pharmacies near you to find which ones have Nuedexta in stock, then texts you the results. This is the fastest way to locate your prescription.

Try a specialty pharmacy. CVS Specialty, Walgreens Specialty, and Accredo (ExpressScripts) are far more likely to have Nuedexta in stock than a standard retail pharmacy.

Activate the co-pay savings card. Commercially insured patients can pay as little as $20 for a 30-day supply or $0 for a 90-day supply at nuedexta.com/activate or by calling 1-855-468-3339.

Ask about the Patient Assistance Program. The Otsuka Patient Assistance Foundation provides Nuedexta at no cost to eligible uninsured and underinsured patients. Call 1-855-468-3339 or visit the Otsuka website for details.

Work with your doctor on PA appeals. If your insurance denied prior authorization, request an appeal. Avanir's support team can provide sample letters of medical necessity and PA appeal support.

What If I Run Out of Nuedexta Before I Can Refill?

Contact your prescribing physician right away. They may be able to provide office samples as a bridge supply while you work out the pharmacy or insurance issue. Do not abruptly stop any medication without consulting your doctor, especially if you have an underlying neurological condition.

Monitoring Nuedexta Availability Going Forward

You can check the FDA Drug Shortages database at accessdata.fda.gov for official shortage announcements. For everyday availability searches, medfinder is the most practical tool for locating Nuedexta at a pharmacy near you. If Nuedexta remains out of reach, consult our guide on alternatives to Nuedexta to discuss off-label options with your prescriber.